Clinical Trial Update: A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of a dual orexin receptor antagonist aimed at reducing biomarkers of neurodegeneration in adults with insom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Dual orexin receptor antagonist (unnamed in document)

Snippet

Sponsor: Woolcock Institute of Medical Research | Conditions: Insomnia | Phase 2 | Status: RECRUITING